Brodalumab

Summary

Brodalumab (CHEMBL1742996) is an approved antibody (ATC L04AC12) targeting IL17RA; indicated across 11 conditions including immune system disorder and psoriasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L04AC12
• Targets: 1 (IL17RA)
• Indications: 11 conditions
• Clinical trials: 40

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1742996
Name	Brodalumab
Type	Antibody
Max phase	4
ATC	L04AC12

Also known as: AMG 827, AMG-827, Brodalumab, KHK-4827, KHK4827, Kyntheum, Siliq, BRODALUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
IL17RA	Interleukin 17 receptor A	Binding	9.16	0%	Q96F46

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): IL17RA.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Interleukin-17 signaling	1	IL17RA
SARS-CoV-2 activates/modulates innate and adaptive immune responses	1	IL17RA

Dominant GO biological processes

GO term	Targets
inflammatory response	1
cell surface receptor signaling pathway	1
response to virus	1
protein catabolic process	1
positive regulation of interleukin-13 production	1
positive regulation of interleukin-23 production	1
positive regulation of interleukin-5 production	1
positive regulation of interleukin-6 production	1
interleukin-17A-mediated signaling pathway	1
innate immune response	1
positive regulation of inflammatory response	1
defense response to fungus	1
granulocyte chemotaxis	1
fibroblast activation	1
T-helper 17 type immune response	1

Indications & clinical

Indications

11 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
immune system disorder	4	MONDO:0005046	EFO:0000540
psoriasis	4	MONDO:0005083	EFO:0000676
psoriatic arthritis	3	MONDO:0011849	EFO:0003778
ankylosing spondylitis	3	MONDO:0005306	EFO:0003898
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
Crohn disease	2	MONDO:0005011	EFO:0000384
hidradenitis suppurativa	2	MONDO:0006559	EFO:1000710
asthma	2	MONDO:0004979	MONDO:0004979
systemic sclerosis	1	MONDO:0005100	EFO:0000717

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 40.

Phase distribution

Phase	Trials
PHASE3	13
PHASE4	8
PHASE2	7
PHASE1	5
EARLY_PHASE1	3
Not specified	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03240809	PHASE4	ACTIVE_NOT_RECRUITING	An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
NCT03331835	PHASE4	COMPLETED	A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
NCT03403036	PHASE4	COMPLETED	Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
NCT03478280	PHASE4	UNKNOWN	Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis
NCT04306315	PHASE4	COMPLETED	Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
NCT04340076	PHASE4	COMPLETED	Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
NCT04533737	PHASE4	TERMINATED	Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
NCT04622033	PHASE4	UNKNOWN	Brodalumab in Palmoplantar Psoriasis
NCT01708590	PHASE3	TERMINATED	Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
NCT01708603	PHASE3	TERMINATED	P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
NCT01708629	PHASE3	TERMINATED	Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
NCT01782924	PHASE3	COMPLETED	A Phase 3 Clinical Study of KHK4827
NCT01782937	PHASE3	COMPLETED	An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis
NCT02024646	PHASE3	COMPLETED	Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
NCT02029495	PHASE3	TERMINATED	Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
NCT02786732	PHASE3	TERMINATED	Study to Evaluate Broadlumab vs Placebo and Ustekinumab
NCT02982005	PHASE3	COMPLETED	A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
NCT02985983	PHASE3	COMPLETED	A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)
NCT03957681	PHASE3	COMPLETED	A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis
NCT04061252	PHASE3	COMPLETED	A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
NCT04305327	PHASE3	TERMINATED	Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
NCT00771030	PHASE1/PHASE2	COMPLETED	Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis
NCT00950989	PHASE2	COMPLETED	Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate
NCT01150890	PHASE2	TERMINATED	Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn’s Disease
NCT01199302	PHASE2	TERMINATED	Long-term Safety Study of Brodalumab in Adults With Crohn’s Disease
NCT01748539	PHASE2	COMPLETED	A Phase 2 Clinical Study of KHK4827
NCT01902290	PHASE2	TERMINATED	Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility
NCT02429882	PHASE2	WITHDRAWN	Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis
NCT03910803	PHASE2	UNKNOWN	Treatment of Moderate Hidradenitis Suppurativa
NCT06673329	PHASE1	RECRUITING	Brodalumab in the Treatment of Immune-Related Adverse Events
NCT01488201	PHASE1	COMPLETED	A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis
NCT01937260	PHASE1	COMPLETED	Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
NCT02173392	PHASE1	COMPLETED	A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab
NCT04368403	PHASE1	COMPLETED	A Study of KHK4827 in Patients With Systemic Sclerosis
NCT03960268	EARLY_PHASE1	COMPLETED	Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab
NCT04249713	EARLY_PHASE1	WITHDRAWN	An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
NCT04979520	EARLY_PHASE1	COMPLETED	Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
NCT03254667	Not specified	ENROLLING_BY_INVITATION	LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
NCT05132231	Not specified	ACTIVE_NOT_RECRUITING	Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity
NCT04149587	Not specified	COMPLETED	A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).